相关实验视频
Updated: Jul 11, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.9K
在使用先进的混合闭环系统时,白天出现低血糖发作
Antonio Rossi1, Laura Montefusco1, Elia Reseghetti2
1Division of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy.
Diabetes research and clinical practice
|November 13, 2023
概括
先进的混合闭环系统可以改善1型糖尿病的血糖控制,但可能会增加白天低血糖. 需要进一步的研究来减轻这种风险,同时优化葡萄糖管理.
科学领域:
- 内分泌学 在内分泌学.
- 糖尿病学 糖尿病学
- 医疗器械 医疗器械
背景情况:
- 先进的混合闭环系统为1型糖尿病提供了改善的血糖控制.
- 低血糖仍然是这些先进系统的一个问题.
研究的目的:
- 为了比较先进的混合闭环系统和预测性低血糖悬浮传感器增强之间的低血糖风险.
- 评估不同自动化胰岛素输送系统的安全性和有效性.
主要方法:
- 三个月的回顾性观察性研究.
- 包括30名使用Medtronic MinimedTM 780G (先进的混合闭环) 的患者.
- 与使用Medtronic MinimedTM预测低血糖悬浮传感器增强的30名患者进行比较.
主要成果:
- 先进的混合闭环系统减少了180 mg/dL以上的时间,并增加了范围内的时间.
- 在这两组中都没有观察到严重的低血糖症.
- 通过先进的混合闭环系统观察到白天低血糖事件的增加,没有显著的时间差异低于70 mg/dL或54 mg/dL.
结论:
- 先进的混合闭环系统在1型糖尿病中改善了血糖指数.
- 增加白天低血糖是先进的混合闭环系统的潜在缺点,需要注意.
相关概念视频
Hypoglycemia and Glucagon
274
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
274
Insulin: Dosing Regimen and Adverse Effects
184
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
184
Oral Hypoglycemic Agents: Glinides
159
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
159
Diabetes: Symptoms, Diagnosis, and Complications
556
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
556
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Insulin Formulations: Types and Delivery
205
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
205

